Table 1.

PARP inhibitors in Phase 2 and Phase 3 clinical development^a.

PARP inhibitor	Clinical trial	Therapy	Tumor type
Olaparib	Phase 2	Monotherapy	Ovarian, peritoneal, fallopian tube, breast, colorectal, lung, Ewing’s sarcoma, prostate, pancreatic, advanced tumors
		Combination	Breast, ovarian, peritoneal, fallopian tube, endometrial, gastric, prostate, lung, pancreatic
	Phase 3	Monotherapy	Breast, ovarian
		Combination	Ovarian, peritoneal, fallopian tube, gastric
		Maintenance	Ovarian, pancreatic
Veliparib	Phase 2	Monotherapy	Ovarian, fallopian tube, peritoneal, breast
		Combination	Breast, ovarian, peritoneal, fallopian tube, colorectal, lung, cervical, prostate, liver, glioblastoma, melanoma, pancreatic, advanced tumors
	Phase 3	Combination	Breast, lung, glioblastoma
Rucaparib	Phase 2	Monotherapy	Breast, ovarian, fallopian, peritoneal, pancreatic
	Phase 3	Combination	Breast
		Maintenance	Ovarian, fallopian tube, peritoneal
Niraparib	Phase 2	Monotherapy	Ovarian
	Phase 3	Monotherapy	Breast
		Maintenance	Ovarian
Talazoparib	Phase 2	Monotherapy	Breast, ovarian, endometrial, advanced tumors
	Phase 3	Monotherapy	Breast
E7016	Phase 2	Combination	Melanoma

^aCompleted and active clinical trials obtained from www.clinicaltrials.gov, data accessed August 2015.